Endocyte (ECYT) : Concannon Wealth Management scooped up 2,000 additional shares in Endocyte during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 2, 2016. The investment management firm now holds a total of 32,639 shares of Endocyte which is valued at $100,528.Endocyte makes up approximately 0.10% of Concannon Wealth Management’s portfolio.
Other Hedge Funds, Including , California State Teachers Retirement System reduced its stake in ECYT by selling 900 shares or 1.12% in the most recent quarter. The Hedge Fund company now holds 79,759 shares of ECYT which is valued at $245,658.Cribstone Capital Management boosted its stake in ECYT in the latest quarter, The investment management firm added 14,808 additional shares and now holds a total of 47,349 shares of Endocyte which is valued at $152,464. Endocyte makes up approx 0.09% of Cribstone Capital Management’s portfolio.
Endocyte closed down -0.07 points or -2.24% at $3.06 with 2,53,457 shares getting traded on Monday. Post opening the session at $3.15, the shares hit an intraday low of $3.04 and an intraday high of $3.19 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Endocyte reported $-0.25 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.26.During the same quarter in the previous year, the company posted $-0.25 EPS.
Endocyte Inc. (Endocyte) is a biopharmaceutical company developing therapies for the treatment of cancer and inflammatory diseases. The Company’s pipeline includes: Vintafolide (Vynfinit or EC145) which delivers potent vinca alkaloid chemotherapy directly to cancer cells by targeting the folate receptor expressed on cancer cells but not on most normal cells; Folate-Tubulysin (EC1456) an SMDC (small molecule drug conjugates) consisting of folate (vitamin B9) linked to a potent cytotoxic agent tubulysin B hydrazide (TubBH); EC0652 a prostate-specific membrane antigen (PSMA)-targeted molecular imaging agent; EC1169 an investigational injectable PSMA-targeted SMDC; Etarfolatide (Folcepri or EC20) a folate-targeted molecular imaging agent; EC1669 a new approach to inflammation therapy targeting an anti-folate drug to activated macrophages expressing folate receptors; EC0371 a folate-targeted water-soluble form of rapamycin and EC1788 a Folate-targeted SMDC.